Related Experiment Videos

Multimarker approach to risk stratification among patients with advanced chronic heart failure

Wei-Hsian Yin1, Jaw-Wen Chen, An-Ning Feng

  • 1Division of Cardiology, Cheng-Hsin Rehabilitation Medical Center, Taipei, Taiwan.

Clinical Cardiology
|August 8, 2007
PubMed

Insights

Combining cardiac troponin I (cTnI), NT-proBNP, and hsCRP offers a simple strategy for risk stratification in advanced chronic heart failure (CHF). This multimarker approach effectively categorizes patients based on elevated biomarker levels, improving clinical outcomes.

Area of Science:

  • Cardiology
  • Biomarker Research
  • Heart Failure Management

Background:

  • Cardiac troponin I (cTnI), NT-proBNP, and hsCRP are known predictors of adverse cardiac events in chronic heart failure (CHF).
  • The combined utility of these novel biomarkers in CHF remains underexplored.

Purpose of the Study:

  • To test the hypothesis that simultaneous assessment of cTnI, NT-proBNP, and hsCRP enhances risk stratification in advanced CHF patients.
  • To evaluate the effectiveness of a multimarker strategy for predicting adverse cardiac events.

Main Methods:

  • Measurements of cTnI, NT-proBNP, and hsCRP were performed in 152 patients with symptomatic advanced CHF.
  • Major adverse cardiac events were tracked over a median follow-up of 186 days.
  • Univariate and multivariate analyses were used to assess biomarker significance.

Main Results:

  • Each elevated biomarker independently predicted clinical outcomes, irrespective of other clinical variables.
  • Patients with one, two, or three elevated biomarkers showed significantly increased risks of adverse events (2.7-fold, 8.6-fold, and 23.4-fold, respectively).
  • Risk increased substantially with a higher number of elevated biomarkers (p < 0.0001 for two or three).

Conclusions:

  • Simultaneous measurement of cTnI, hsCRP, and NT-proBNP provides complementary information for risk stratification in advanced CHF.
  • A simple multimarker strategy, based on the number of elevated biomarkers, enables rapid risk assessment.
  • This approach aids clinicians in identifying high-risk patients with advanced CHF.
Abstract

Related Concept Videos

Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.